Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 30, 2007

Compugen and Teva to Discover Biomarkers for Drug Toxicity

  • Compugen and Teva Pharmaceutical will  work together to discover biomarkers for the detection of drug toxicity in preclinical stages of the development process.

    Initial focus of the collaboration will be on biomarkers for the early detection of potential nephrotoxicity. The parties may jointly choose to expand the scope of the partnership to include biomarkers for the detection of hepatotoxicity and/or cardiotoxicity in response to drug treatment.

    Compugen has granted Teva a license to use the discovered markers for R&D activities while retaining commercialization rights for licensing them to other companies as well as rights for internal use.

    Compugen expects to utilize its computational tools, discovery engines, and nucleic-acid-testing technologies for the purpose of predicting and validating toxicity biomarkers. This analysis will incorporate data derived from biological samples collected by Teva in a preclinical study designed specifically for this project as well as Compugen’s expression and clinical data.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »